Plasma Pentraxin3 as a Marker for NASH
Author Information
Author(s): Yoneda Masato, Uchiyama Takashi, Kato Shingo, Endo Hiroki, Fujita Koji, Yoneda Kyoko, Mawatari Hironori, Iida Hiroshi, Takahashi Hirokazu, Kirikoshi Hiroyuki, Inamori Masahiko, Nozaki Yuichi, Kobayashi Noritoshi, Kubota Kensuke, Saito Satoru, Maeyama Shiro, Sagara Mina, Aburatani Hiroyuki, Kodama Tatsuhiko, Nakajima Atsushi
Primary Institution: Yokohama City University Graduate School of Medicine
Hypothesis
Plasma PTX3 levels increase in patients with NASH.
Conclusion
Plasma PTX3 levels may serve as a noninvasive marker to differentiate NASH from non-NASH and indicate the severity of liver fibrosis.
Supporting Evidence
- Plasma PTX3 levels were significantly higher in NASH patients compared to non-NASH patients.
- The study included 70 NAFLD patients and 10 healthy controls.
- The area under the curve for plasma PTX3 to detect NASH was 0.755.
Takeaway
This study found that a substance called PTX3 in the blood is higher in people with a liver disease called NASH compared to those without it, which could help doctors tell the difference between the two.
Methodology
Plasma PTX3 levels were measured in 70 NAFLD patients and 10 healthy controls, with liver biopsies performed for diagnosis.
Participant Demographics
70 Japanese NAFLD patients (42 NASH and 28 non-NASH) and 10 healthy controls.
Statistical Information
P-Value
0.0021
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website